Assessment of Bilateral Inferior Petrosal Sinus Sampling (BIPSS) in the Diagnosis of Cushing's Disease  by Lin, Liang-Yu et al.
J Chin Med Assoc • January 2007 • Vol 70 • No 14
© 2007 Elsevier. All rights reserved.
ORIGINAL ARTICLE
Assessment of Bilateral Inferior Petrosal Sinus
Sampling (BIPSS) in the Diagnosis of 
Cushing’s Disease
Liang-Yu Lin1, Michael Mu-Huo Teng2,4, Chun-I Huang3,4, Wen-Ya Ma5, Kang-Ling Wang6, 
Hong-Da Lin1,4, Justin G.S. Won1,4*
1Division of Endocrinology and Metabolism, Department of Medicine, 2Division of Neuroradiology, Department of 
Radiology, and 3Department of Emergency Medicine, Taipei Veterans General Hospital, 4National Yang-Ming University 
School of Medicine, Taipei, 5Division of Endocrinology and Metabolism, Department of Internal Medicine, Tao-Yuan 
Veterans Hospital, and 6Department of Medicine, Tao-Yuan Armed Forces General Hospital, Tao-Yuan, Taiwan, R.O.C.
Background: The differential diagnosis of adrenocorticotropin (ACTH)-dependent Cushing’s syndrome (CS) remains a chal-
lenging issue for clinical endocrinologists. In this respect, bilateral inferior petrosal sinus sampling (BIPSS) appears to be
the most sensitive and specific test. Here, we report our 15-year experience of analyzing the performance of BIPSS, both
in the correct diagnosis and in the precise lateralization of tumors in patients with Cushing’s disease (CD).
Methods: Between 1992 and 2006, 18 patients with CD (16 females, 2 males; age range, 14–56 years) were admitted
to Taipei Veterans General Hospital and subjected to BIPSS plus ovine corticotropin-releasing hormone (oCRH) stimula-
tion. Four of them had previously undergone transsphenoidal hypophysectomy (TSH) and had a recurrence thereafter.
BIPSS was performed by inserting a catheter in the right and left inferior petrosal sinus for ACTH assay via a femoral vein
puncture. An inferior petrosal sinus/peripheral ACTH ratio (C/P ratio) ≥ 2 at baseline or ≥ 3 after oCRH injection indi-
cated a pituitary origin of ACTH secretion, and an interpetrosal ACTH gradient (IPS ratio) ≥ 1.4 at baseline or after oCRH
indicated evidence of lateralization.
Results: Positive BIPSS results were found in 16 patients at baseline and in 17 patients after oCRH injection. In 17 out of
18 patients, TSH was subsequently carried out and a pituitary source was confirmed on histopathologic examination. The
only 1 false-negative test result was noted in a patient who had undergone previous TSH. Thus, the sensitivities of BIPSS for
the diagnosis of CD before and after oCRH stimulation were 89% and 94%, respectively. Moreover, using an IPS ratio ≥ 1.4
as a criterion, BIPSS correctly lateralized the tumor in 9 of 17 and 10 of 17 patients at baseline and after oCRH stimulation,
respectively, including in 2 patients who had a centrally located tumor and who had an IPS ratio < 1.4. Thus, the sensitivities
of lateralization of BIPSS were 53% and 59%, respectively. None of the 4 patients who had previous TSH were precisely
localized by BIPSS. If these 4 patients were excluded, the sensitivities of BIPSS for localizing in the patients who had not
undergone previous operation increased to 70% (9/13) at baseline and 77% (10/13) after oCRH stimulation, respectively.
Conclusion: BIPSS combined with oCRH stimulation is a safe and reliable examination both in the differential diagnosis of
CD and in the correct lateralization of pituitary microadenoma in patients without previous pituitary surgery. Nevertheless,
this procedure may provide misleading results in patients who have received previous pituitary surgery. [J Chin Med
Assoc 2007;70(1):4–10]
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Introduction
The differential diagnosis of adrenocorticotropin
(ACTH)-dependent Cushing’s syndrome (CS), that
is, discrimination between pituitary-dependent and
ectopic CS, remains a challenging issue for clinical endo-
crinologists. These 2 disease entities may be indistin-
guishable clinically, and their plasma ACTH levels are
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often similar. In addition, because of the small size 
of these pituitary tumors, 40–50% are not localized
preoperatively even by sophisticated magnetic reso-
nance imaging (MRI).1 Although some noninvasive
tests such as the high-dose dexamethasone suppression
test (HDDST) and the ovine corticotropin-releasing
hormone (oCRH) stimulation test are widely used for
this purpose, the most convincing method has been
the bilateral inferior sinus sampling (BIPSS) proce-
dure, in which a diagnostic accuracy of near 100% has
been reported, especially when combined with oCRH
stimulation.2,3
BIPSS, in addition to providing information about
the precise source of ACTH-secreting pituitary micro-
adenoma, also provides important information to
enable a neurosurgeon to localize the pituitary tumor
preoperatively.4,5 A unilateral elevation of ACTH (a
ratio of interpetrosal ACTH ≥ 1.4) suggests the exis-
tence of a laterality and indicates the presence of an
ACTH-producing microadenoma in the ipsilateral side
of the pituitary gland, which might allow the neuro-
surgeon to perform a hemiphysectomy rather than a
total hypophysectomy in case the microadenoma is too
small to identify.
In the present study, the performances of BIPSS
combined with oCRH stimulation in the differential
diagnosis of Cushing’s disease (CD) and in the pre-
operative localization of pituitary microadenoma
were determined. To our knowledge, this is the first
investigation attempting to discover the utility of this
procedure in patients with CD in Taiwan.
Methods
Patients
Between 1992 and 2006, 18 patients were admitted to
Taipei Veterans General Hospital with CD (16 females,
2 males; age range, 14–56 years). They were subjected
to BIPSS plus oCRH stimulation. Four patients (case
no. 1, 2, 5, 6) had undergone transsphenoidal hypophy-
sectomy (TSH) previously and had a recurrence. The
diagnosis of CS was established by full-blown clinical
manifestations, elevated 24-hour urinary free cortisol
(UFC) levels, loss of circadian rhythm of serum cortisol,
and non-suppressibility of serum cortisol or UFC to the
low-dose dexamethasone suppression test (LDDST)
(Table 1). Furthermore, most of the patients were
Table 1. Biochemical features of 18 patients with Cushing’s disease
Baseline
oCRH stimulationPatient
Sex Age (yr)
Plasma ACTH Plasma cortisol
UFC (μg/d)*
LDDST† HDDST‡
test§no. (pg/mL) (mg/dL)
8 AM 10 PM 8 AM 10 PM
1 F 40 6.2 X 15.8 12.0 80.0 NS NS X
2 F 26 106.7 X 53.0 X 477.0 X X Y
3 F 53 50.0 68.4 24.7 18.3 74.6 NS NS Y
4 F 44 23.5 21.3 17.9 36.8 124.8 NS S Y
5 F 37 46.4 24.1 8.9 9.0 57.5 NS S Y
6 M 19 152.3 128.3 33.5 23.7 257.4 NS NS Y
7 M 14 63.0 75.0 13.4 28.4 787.0 NS NS Y
8 F 41 64.5 31.8 37.4 13.2 301.8 NS S Y
9 F 35 62.5 52.8 18.3 12.4 121.5 NS S Y
10 F 26 44.5 60.0 19.1 18.2 335.7 X NS N
11 F 36 131.0 107.3 48.0 33.2 1,069.5 X X N
12 F 33 59.5 73.3 21.7 23.8 666.7 X S Y
13 F 31 59.8 17.8 22.8 13.4 232.0 X S Y
14 F 36 20.5 18.8 7.4 14.5 469.1 X S N
15 F 55 138.0 102.5 20.5 11.4 259.5 X S Y
16 F 28 53.0 87.0 21.9 20.6 473.0 X S Y
17 F 49 40.8 34.8 21.2 12.2 147.0 X S N
18 F 43 69.8 49.8 26.6 26.1 359.9 NS S N
*UFC = urinary free cortisol, normal < 100 mg/day; †LDDST = low-dose dexamethasone suppression test, dexamethasone 0.5 mg per oral q6h for 2 days;
‡HDDST = high-dose dexamethasone suppression test, dexamethasone 2 mg per oral q6h for 2 days; §oCRH stimulation test = intravenous bolus of ovine 
corticotropin-releasing hormone 100 mg at 8 AM. ACTH = adrenocorticotropin; X = not done; NS = nonsuppressible; Y = positive response defined as an incre-
ment ≥ 20% of serum cortisol over baseline or ≥ 50% or more of plasma ACTH over baseline; S = suppressible, 8 AM cortisol < 50% of baseline on day 3 or UFC
< 10% of baseline on day 2; N = negative response.
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also subjected to the HDDST and oCRH stimulation
tests in order to distinguish CD from adrenal or
ectopic CS.
Imaging studies including high-resolution contrast-
enhanced thin-section computed tomography (CT)
and MRI were obtained in each patient before BIPSS
and were read by 2 independent neuroradiologists. A
pituitary tumor was revealed in 14 patients. In patient
no. 17, 2 distinct microadenomas were disclosed on
both sides of the pituitary. No discrete lesion was
found in the remaining 3 subjects. In our study, the
operative findings of the surgeon were used as the ref-
erence standard for lateralization of the pituitary
tumor, except in patient no. 10, who was unsuitable
for surgery due to poor pneumonization of the sphe-
noid sinus (conchal sella).
BIPSS
The procedures were performed as described by
Oldfield et al.6 In brief, a catheter was placed in the
orifice of each of the right and left inferior petrosal
sinuses via a femoral vein approach. Blood samples for
ACTH assay were obtained simultaneously from both
sides of the inferior petrosal sinus and from a periph-
eral vein before and 3, 5 and 10 minutes after oCRH
100 μg was given as a bolus injection. Synthetic oCRH
was purchased from Bachem (Torrance, CA, USA)
and was reconstituted by dissolving oCRH powder 
in distilled water and sterilizing through a 0.22 μm
Millipore filter. Blood samples were collected in
chilled test tubes containing sodium ethylenediamine
tetraacetic acid (EDTA), centrifuged at 4°C, and the
plasma was stored at −20°C until ACTH levels were
determined by immunoradiometric assay (IRMA).
ACTH concentrations in the bilateral sampling and in
the periphery were calculated for C/P ratio for each
set of samples. A C/P ratio ≥ 2 at baseline or ≥ 3 after
oCRH injection was considered to indicate a pituitary
origin of ACTH secretion. Then, the ACTH concen-
tration ratio between the right and left inferior petro-
sal sinuses (IPS ratio) was calculated. A ratio ≥ 1.4
either before or after oCRH injection was considered
to be evidence of lateralization of ACTH secretion
and indicative of a tumor on the ipsilateral side of the
pituitary gland.
Hormone assays
Plasma ACTH levels were determined by IRMA
(Nichols Institute, San Juan Capistrano, CA, USA).
The intra- and interassay coefficients of variation were
3.0% and 7.8%, respectively. The minimal detected
concentration was 1 pg/mL, and the reference range
in the morning was 9–52 pg/mL. Serum cortisol was
measured by a homemade radioimmunoassay (RIA),
using an antiserum raised in rabbit (Ig G-F-1, Ig G
1:100 dilution; Ig G Corporation, Nashville, TN, USA)
and a tracer from Amersham Biosciences (cortisol-3-
(O-carboxymethyl) oximino-(2-[125I] iodohistamine),
IM129, Buckinghamshire, UK). The intra- and interas-
say coefficients of variation were 4.1% and 10.2%,
respectively. The minimal detectable cortisol level was
0.02 μg/dL. A 1:20 dilution was created by adding
50 μL serum to 1,950 μL buffer solution before RIA
was performed. UFC levels were determined by RIA
as described above after extraction by dichlormethane.
The intra- and interassay coefficients of variation were
6.2% and < 10%, respectively. The normal reference
value was < 100 μg/day in our laboratory.
Results
Diagnosis of ACTH-dependent CS
The detailed biochemical features of the 18 patients
with CD are shown in Table 1. All patients had mid-
night cortisol levels that were both > 7.5 μg/dL and
> 50% of the corresponding morning cortisol concen-
trations, suggesting a loss of circadian rhythm of cor-
tisol secretion. Increased 24-hour UFC excretion
(> 100 μg/day) was found in 15 of the 18 patients
(83%). Nine subjects, including 3 patients who had
normal 24-hour UFC excretion, underwent standard
LDDST, and all showed a nonsuppressible serum cor-
tisol concentration and UFC excretion, thus confirming
the diagnosis of active CS. Except for patient no. 1 who
had recurrent CD and ACTH level of 6.2 pg/mL, the
plasma ACTH levels in all the other patients ranged
from 20 to 152 pg/mL, consistent with the diagnosis
of ACTH-dependent CS.
Results of noninvasive localization methods
As shown in Table 1, using a criterion of suppression
of ≥ 50% of serum cortisol level or suppression of
≥ 90% of UFC excretion, the sensitivity of HDDST
was 69% (11/16). A similar sensitivity (71%; 12/17)
was achieved by the oCRH test when a criterion of an
increase of ≥ 50% of plasma ACTH concentration or an
increase of ≥ 20% of serum cortisol level was used.
As shown in Table 2, imaging studies showed that
14 of the 18 patients had CT/MRI evidence suggest-
ing pituitary tumors (78%), which appeared to have
comparable sensitivity to the endocrine dynamic tests.
However, correct lateralization was confirmed in 9 of 17
patients (52%) and in 6 of the 13 fresh cases (46%) after
surgery. Three of the 4 patients who had recurrence
were correctly lateralized (75%) by imaging studies.
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BIPSS results
As shown in Figures 1 and 2, the sensitivities of BIPSS
were 89% (16/18) and 94% (17/18), respectively, using
C/P ratio ≥2 at baseline or ≥3 after oCRH stimulation.
In patient no. 14, the C/P ratio was non-diagnostic at
baseline but turned positive after stimulation. In patient
no. 6, who had a recurrence and no visible tumor on
imaging studies, the C/P ratio was non-diagnostic at
both baseline and after oCRH stimulation.
As far as lateralization was concerned, the sensitivities
of BIPSS lateralization were 53% (9/17) at baseline and
59% (10/17) after oCRH stimulation using the criterion
of IPS ratio ≥ 1.4, including 2 patients (patients no. 15,
18) who had a centrally located tumor and an IPS ratio
<1.4. None of the 4 patients who had undergone previ-
ous TSH were correctly lateralized by BIPSS. If these 
4 patients were excluded, the sensitivities of BIPSS
lateralization in the remaining patients who had not
undergone pituitary surgery increased to 70% (9/17) at
baseline and 77% (10/17) after oCRH stimulation.
Two patients (patients no. 15, 16) were falsely later-
alized by CT/MRI. Moreover, in 3 (patients no. 7, 8,
18) of the 4 patients (patients no. 6, 7, 8, 18) who
had negative imaging studies, BIPSS correctly lateral-
ized the tumor, further confirming the higher sensitivity
and specificity of BIPSS.
Efficacy and safety of BIPSS
BIPSS was successfully performed in all cases, and the
sampling sites were confirmed by angiography. Patients
experienced transient headache, nausea, ear discomfort
and minor bruising at the puncture site, but there were
no major complications.
Discussion
CD is by far the most common cause of ACTH-
dependent CS. During the past 15 years, only 1 patient
suspected to have ectopic CS was encountered in our
institution. A female preponderance as found in our
cases is consistent with previous observations.7 All of the
18 patients evaluated in this study were diagnosed with
ACTH-dependent CS based on biochemical evidence
of hypercortisolism (loss of circadian rhythm of serum
cortisol, elevated 24-hour UFC excretion and/or non-
suppressible serum cortisol in LDDST) associated with
normal or high plasma ACTH levels. Despite the 
relatively low ACTH concentration in patient no. 1, 
a pathologically proven case of CD, recurrence was
confirmed by LDDST. The sensitivities of UFC and
midnight serum cortisol in the diagnosis of active CS in
our series were 83% and 100%, respectively, which were
Table 2. Imaging findings and results of bilateral inferior petrosal sinus sampling (BIPSS) in 18 patients with Cushing’s disease
Patient
Imaging BIPSS results—ACTH (pg/mL)
Operative Therapeuticfindings Baseline C/P ratio IPS ratio (side)
no.
CT/MRI R L P Basal Post-oCRH Basal Post-oCRH
findings outcomes
1 M 362.9 24.5 72.9 5.0 496.0 14.8 (R) 260.0 (R) M RE
2 L 255.3 95.2 55.9 4.6 9.8 2.7 (R) 5.5 (R) L PER
3 R 343.9 62.9 72.8 4.7 12.5 5.5 (R) 15.2 (R) R RE
4 R 91.4 160.8 33.3 4.8 29.3 3.6 (R) 1.5 (R) R RE
5 L 274.5 65.5 42.5 6.5 15.8 4.2 (R) 13.4 (R) L RE
6 N 178.5 136.5 179.5 1.0 1.2 1.3 1.3 L RE
7 N 303.0 44.0 42.5 7.1 9.6 9.6 (R) 4.4 (R) R RE
8 N 42.5 388.0 46.5 8.3 5.3 9.1 (L) 4.5 (L) L RE
9 R 193.0 49.0 68.0 2.8 15.0 3.7 (R) 17.9 (R) R RE
10 R 282.0 59.0 61.0 4.6 6.5 4.8 (R) 6.1 (R) Not done
11 L 385.5 704.0 78.0 9.0 12.4 1.8 (L) 1.9 (L) L RE
12 L 643.5 87.0 57.5 11.2 17.7 7.0 (R) 2.6 (R) M RE
13 M 51.0 288.0 38.0 7.6 11.8 5.7 (L) 6.3 (L) R RE
14 R 17.5 13.5 10.0 1.8 43.7 1.3 32.8 (R) R PER
15 L 327.0 341.0 59.0 5.8 6.3 1.0 1.2 M RE
16 M 475.0 76.5 52.0 9.1 10.8 10.8 (R) 9.3 (R) R RE
17 R & L 44.0 54.0 13.0 4.2 8.6 1.3 1.8 (L) R & L RE
18 N 161.5 160.0 21.5 7.5 10.7 1.0 1.3 M PER
CT = computed tomography; MRI = magnetic resonance imaging; ACTH = adrenocorticotropin; C/P = central to peripheral; IPS = inter-inferior petrosal sinus;
R = right; L = left; P = peripheral; oCRH = ovine corticotropin-releasing hormone; M = midline; RE = remission; PER = persistence; N = negative.
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compatible with those of previous studies (71% and
96%).8,9 Although only 9 patients had received LDDST,
all of them, including 3 patients who had normal UFC
excretion, demonstrated nonsuppressible serum cortisol
level. It appears that, in our series, midnight serum cor-
tisol and LDDST had higher sensitivities than UFC 
in the diagnosis of CS.
Among the noninvasive tests for differentiating
CD from ectopic CS, the sensitivities of HDDST and
oCRH stimulation were 69% and 71%, respectively. In
our previous study, the sensitivities were 67% and 90%
for HDDST and oCRH, respectively.10 The lower sen-
sitivity of the oCRH test in this series might be related
to selection bias and small sample size. Imaging studies,
such as CT/MRI, help to differentiate ACTH-
depending CS by detecting pituitary tumor in patients
with CD, with a sensitivity ranging from 35% to
75%.11–13 In our series, 14 of 18 patients were found
to have a microadenoma, giving a sensitivity of 78%.
However, the results of CT/MRI may be misleading
for the correct localization of tumor, as shown in this
study, and the fact that pituitary incidentaloma can be
found in nearly 10% of the general population.14 Our
results suggested, consistent with previous series, that
BIPSS plus oCRH stimulation provides a more precise
method for diagnosing CD patients, with superior
sensitivities of 89% and 94%, before and after oCRH
stimulation, respectively.15–20
Most patients with CD harbor a microadenoma
that is confined to 1 side of the pituitary gland and
which has venous drainage directly into the ipsilateral
inferior petrosal sinus.6,21 BIPSS has been widely used
for preoperative assessment and for predicting lateral-
ization, with a sensitivity ranging from 57% to
62%.20,22,23 Although not as accurate as Oldfield et al’s
series, we found that the sensitivities of lateralization
of BIPSS were 53% at baseline and 59% after oCRH
stimulation. Notably, in 4 patients who had undergone
Figure 1. Responses of plasma adrenocorticotropin (ACTH) to ovine corticotropin-releasing hormone (oCRH) stimulation in the right and
left inferior petrosal sinuses and peripheral vein in patients no. 1 to 9.
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previous TSH, none were correctly lateralized by BIPSS,
a finding that was similar to the observation of Vignati
et al.24 Altered venous drainage after surgical interven-
tion probably contributed to the unreliable BIPSS
results in those patients. Therefore, the BIPSS results in
such patients may be misleading and should not be
recommended. Nevertheless, BIPSS combined with
oCRH stimulation correctly lateralized the tumor in
9 of the 13 and in 10 of the 13 unoperated on CD
patients at baseline and after oCRH stimulation,
respectively, including 3 patients who had no visible
tumor on CT/MRI. Therefore, as an attempt to pro-
vide additional preoperative information for neuro-
surgeons, BIPSS plus oCRH stimulation appear to be
a reasonable approach, especially in patients who have
negative results on imaging studies. When BIPSS and
CT/MRI were combined, correct lateralization was
found in 12 out of 17 cases (71%).
Being highly invasive, BIPSS requires an experi-
enced radiology team to minimize the possible risks.
Nausea, headache, transient ear discomfort and groin
hematomas have been occasionally reported, but major
complications such as subarachnoid hemorrhage or
pontine infarction are rarely encountered.23,25 Success-
ful catheterization rates described in the literature
range from 65% to 100%.13,15,16,26,27 Based on our
limited experience, we believe that BIPSS is a safe and
well-established procedure in our institution.
Limitations do exist in this study because of the
small sample size and there being no available data from
ectopic CS. There was also inevitable selection bias for
this invasive procedure that was only performed when
other tests proved to be inconclusive, rather than as
routine screening at the beginning of the study, leading
to difficulty in precise estimation of specificity, positive
predictive value or other characteristics of test accuracy.
Figure 2. Responses of plasma adrenocorticotropin (ACTH) to ovine corticotropin-releasing hormone (oCRH) stimulation in the right and
left inferior petrosal sinuses and peripheral vein in patients no. 10 to 18.
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Larger series including more patients with CD and
patients with ectopic CS are necessary to obtain further
information.
In summary, we confirm that BIPSS combined with
oCRH stimulation is a safe and reliable procedure not
only in the differential diagnosis of ACTH-dependent
CS but also in the preoperative lateralization of ACTH-
secreting microadenoma in patients with CD who have
not undergone previous pituitary surgery.
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